Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia.